Aleva Neurotherapeutics raises USD18m in series C financing round
Aleva Neurotherapeutics, a developer of next-generation implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s Disease and Essential Tremor, has raised USD 18 million in a Series C financing round. The round was led by Greatbatch (NYSE:GB), a strategic lead investor contributing a total of USD5